Nagichettiar Satyamurthy
· ProfessorUniversity of California, Los Angeles · Nuclear Medicine & Theranostics
Active 1979–2023
About
Nagichettiar Satyamurthy, trained as an organic chemist, did his post-doctoral research in the Department of Chemistry at Oklahoma State University in 1980. He then joined the Division of Nuclear Medicine at UCLA in 1981 and has been a faculty member in the Division of Nuclear Medicine in the Department of Radiological Sciences and in the Department of Molecular and Medical Pharmacology for over thirty-six years. His research focuses on the development of new methodologies for nucleophilic [18F]radiofluorination of aromatic rings in biomarkers useful for positron emission tomography (PET). He has identified iodine-based groups such as iodyl and iodonium ylide as potential leaving groups for nucleophilic substitution with [18F] fluoride ion, enabling the synthesis of PET biomarkers like 6-[18F]fluoro-L-dopa and a benzothiazole derivative for imaging Alzheimer's disease. His novel fluorination techniques have been adopted by many laboratories across the US, Canada, and Europe. Additional research areas include designing and synthesizing drug molecules to inhibit enzymes involved in nucleoside/nucleotide metabolism and developing 18F-labeled molecular imaging probes for PET investigation of SGL2-driven cancers and dementia.
Research topics
- Internal medicine
- Medicine
- Nuclear medicine
- Cancer research
- Pathology
- Medical physics
Selected publications
2023-03-31
preprintOpen access<p>PDF file - 329K</p>
Modular radiochemistry synthesis system
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · 2023-01-23 · 1 citations
articleOpen access1st authorCorrespondingA modular chemical production system includes multiple modules for performing a chemical reaction, particularly of radiochemical compounds, from a remote location. One embodiment comprises a reaction vessel including a moveable heat source with the position thereof relative to the reaction vessel being controllable from a remote position. Alternatively the heat source may be fixed in location and the reaction vial is moveable into and out of the heat source. The reaction vessel has one or more sealing plugs, the positioning of which in relationship to the reaction vessel is controllable from a remote position. Also the one or more reaction vessel sealing plugs can include one or more conduits there through for delivery of reactants, gases at atmospheric or an elevated pressure, inert gases, drawing a vacuum and removal of reaction end products to and from the reaction vial, the reaction vial with sealing plug in position being operable at elevated pressures. The modular chemical production system is assembled from modules which can each include operating condition sensors and controllers configured for monitoring and controlling the individual modules and the assembled system from a remote position. Other modules include, but are not limited to a Reagent Storage and Delivery Module, a Cartridge Purification Module, a Microwave Reaction Module, an External QC/Analysis/Purification Interface Module, an Aliquotting Module, an F-18 Drying Module, a Concentration Module, a Radiation Counting Module, and a Capillary Reactor Module.
2023
- Nuclear medicine
- Medicine
- Internal medicine
<div>Abstract<p><b>Purpose:</b> The primary objective of this study was to investigate whether changes in 3′-deoxy-3′-[<sup>18</sup>F]fluorothymidine (<sup>18</sup>F-FLT) kinetic parameters, taken early after the start of therapy, could predict overall survival (OS) and progression-free survival (PFS) in patients with recurrent malignant glioma undergoing treatment with bevacizumab and irinotecan.</p><p><b>Experimental Design:</b> High-grade recurrent brain tumors were investigated in 18 patients (8 male and 10 female), ages 26 to 76 years. Each had 3 dynamic positron emission tomography (PET) studies as follows: at baseline and after 2 and 6 weeks from the start of treatment, <sup>18</sup>F-FLT (2.0 MBq/kg) was injected intravenously, and dynamic PET images were acquired for 1 hour. Factor analysis generated factor images from which blood and tumor uptake curves were derived. A three-compartment, two-tissue model was applied to estimate tumor <sup>18</sup>F-FLT kinetic rate constants using a metabolite- and partial volume–corrected input function. Different combinations of predictor variables were exhaustively searched in a discriminant function to accurately classify patients into their known OS and PFS groups. A leave-one-out cross-validation technique was used to assess the generalizability of the model predictions.</p><p><b>Results:</b> In this study population, changes in single parameters such as standardized uptake value or influx rate constant did not accurately classify patients into their respective OS groups (<1 and ≥1 year; hit ratios ≤78%). However, changes in a set of <sup>18</sup>F-FLT kinetic parameters could perfectly separate these two groups of patients (hit ratio = 100%) and were also able to correctly classify patients into their respective PFS groups (<100 and ≥100 days; hit ratio = 88%).</p><p><b>Conclusions:</b> Discriminant analysis using changes in <sup>18</sup>F-FLT kinetic parameters early during treatment seems to be a powerful method for evaluating the efficacy of therapeutic regimens. <i>Clin Cancer Res; 17(20); 6553–62. ©2011 AACR</i>.</p></div>
2023
- Nuclear medicine
- Medicine
- Internal medicine
<div>Abstract<p><b>Purpose:</b> The primary objective of this study was to investigate whether changes in 3′-deoxy-3′-[<sup>18</sup>F]fluorothymidine (<sup>18</sup>F-FLT) kinetic parameters, taken early after the start of therapy, could predict overall survival (OS) and progression-free survival (PFS) in patients with recurrent malignant glioma undergoing treatment with bevacizumab and irinotecan.</p><p><b>Experimental Design:</b> High-grade recurrent brain tumors were investigated in 18 patients (8 male and 10 female), ages 26 to 76 years. Each had 3 dynamic positron emission tomography (PET) studies as follows: at baseline and after 2 and 6 weeks from the start of treatment, <sup>18</sup>F-FLT (2.0 MBq/kg) was injected intravenously, and dynamic PET images were acquired for 1 hour. Factor analysis generated factor images from which blood and tumor uptake curves were derived. A three-compartment, two-tissue model was applied to estimate tumor <sup>18</sup>F-FLT kinetic rate constants using a metabolite- and partial volume–corrected input function. Different combinations of predictor variables were exhaustively searched in a discriminant function to accurately classify patients into their known OS and PFS groups. A leave-one-out cross-validation technique was used to assess the generalizability of the model predictions.</p><p><b>Results:</b> In this study population, changes in single parameters such as standardized uptake value or influx rate constant did not accurately classify patients into their respective OS groups (<1 and ≥1 year; hit ratios ≤78%). However, changes in a set of <sup>18</sup>F-FLT kinetic parameters could perfectly separate these two groups of patients (hit ratio = 100%) and were also able to correctly classify patients into their respective PFS groups (<100 and ≥100 days; hit ratio = 88%).</p><p><b>Conclusions:</b> Discriminant analysis using changes in <sup>18</sup>F-FLT kinetic parameters early during treatment seems to be a powerful method for evaluating the efficacy of therapeutic regimens. <i>Clin Cancer Res; 17(20); 6553–62. ©2011 AACR</i>.</p></div>
2023-03-31
preprintOpen access<p>MOV file - 330KB</p>
2023-03-31
preprintOpen access<p>MOV file - 330KB</p>
Nucleophilic fluorination of aromatic compounds
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · 2023-01-23
articleOpen access1st authorCorrespondingIodylbenzene derivatives substituted with electron donating as well as electron withdrawing groups on the aromatic ring are used as precursors in aromatic nucleophilic substitution reactions. The iodyl group (IO.sub.2) is regiospecifically substituted by nucleophilic fluoride to provide the corresponding fluoroaryl derivatives. No-carrier-added [F-18]fluoride ion derived from anhydrous [F-18](F/Kryptofix, [F-18]CsF or a quaternary ammonium fluoride (e.g., Me.sub.4NF, Et.sub.4NF, n-Bu.sub.4NF, (PhCH.sub.2).sub.4NF) exclusively substitutes the iodyl moiety in these derivatives and provides high specific activity F-18 labeled fluoroaryl analogs. Iodyl derivatives of a benzothiazole analog and 6-iodyl-L-dopa derivatives have been synthesized as precursors and have been used in the preparation of no-carrier-added [F-18]fluorobenzothiazole as well as 6-[F-18]fluoro-L-dopa.
2023-03-31
preprintOpen access<p>PDF file - 329K</p>
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · 2023-01-23
articleOpen access1st authorCorrespondingA process for forming a 6-fluoro derivative of compounds in the L-Dopa family comprising the steps of protecting the groups attached to the benzene ring in the compound followed by serially reacting the protected compound with (a) iodine and silver trifluoroacetic acid; (b) Bb.sub.3 ; (c) dit-butyldicarbonate; (d) hexamethyltin; (e) a fluoro compound; (f) hydrobromic acid; and (g) raising the pH to .ltoreq.7.
2023-03-31
preprintOpen access<p>MOV file - 340KB</p>
Recent grants
NIH · $24.4M · 2010
NIH · $1.8M · 2014
NIH · $20.5M · 2015
Frequent coauthors
- 213 shared
Jorge R. Barrio
University of California, Los Angeles
- 81 shared
Sung‐Cheng Huang
- 80 shared
Michael E. Phelps
- 65 shared
Gary W. Small
- 62 shared
Vladimir Kepe
Cleveland Clinic
- 55 shared
Linda M. Ercoli
- 47 shared
K.P. Wong
University of California, Los Angeles
- 43 shared
Mohammad Namavari
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Nagichettiar Satyamurthy
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup